Smithkline Beecham Corporation

Cytokinetics, Inc.

Glaxosmithkline LLC

Smithkline Beecham Intercredit B.v.

Dashyant Dhanak

Steven David Knight

David John Morgans, Jr

Gustave Bergnes

Kenneth Allen Newlander

Andrew I McDonald

Nicholas D Adams

Bainian Feng

Xiangping Qian

Bing Yao

Cynthia A Parrish

Han-Jie Zhou

Christopher A Brook

Hong Jiang

Bradley Paul Morgan

Luke W Ashcraft

Kevin J Duffy

Jianchao Wang

Duke Fitch

Rosanna Tedesco

Jennifer Kuo Chen Huang

Robert John Ife

Pu-Ping Lu

Timothy Francis Gallagher

Jian Jin

Jerry Leroy Adams

Katherine L Widdowson

Richard McCulloch Keenan

Colin Andrew Leach

Deirdre M Hickey

Michael Gerard Darcy

Gregory Lee Warren

David Graham Tew

Dirk Andries Heerding

Colin A Leach

Jeffrey Michael Axten

John Richard White

Domingos J Silva

Jun Tang

Thomas Joseph Carr

Anthony Sapienza

Martha A Sarpong

Amita M Chaudhari

Toshihiro Hamajima

Ralph A Rivero

Stanley J Schmidt

Calvin O Manning

Pu Ping Lu

Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of one or more mitotic kinesins are disclosed.

Imidazole-benzamide anti-cancer agents

Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of KSP are disclosed.

Compounds, compositions and methods

Deuterated forms of N-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide and pharmaceutical compositions containing the same.

Deuterated benzene sulfonamide thiazole compounds

Imidazopyridinyl benzamide mitotic kinesin inhibitors

Provided are compounds of Formula V and pharmaceutically acceptable salts thereof which may be useful for the treatment of cancer or other proliferative disorders. 

Imidazoyl-benzamide anti-cancer agents

Imidazopyridinyl-benzamide anti-cancer agents

The present invention relates to a compound represented by Formula (I): and pharmaceutically acceptable salts. Compounds of the present invention inhibit Aurora kinase, making them especially suitable for the treatment of a number of diseases, including solid tumor cancers and hematological cancers.

Azaindole inhibitors of Aurora kinases

Provided are compounds of Formula I and pharmaceutically acceptable salts thereof which may be useful for the treatment of cancer or other proliferative disorders. 

Compounds, compositions, and methods

Provided herein are certain substituted N-phenethylbenzamide of formula V: that may be useful for treating certain cellular proliferation diseases and disorders by modulating the activity of CENP-E.

N-(4-(imidazo[1,2A]pyridin-YL)phenethyl)benzamide inhibitors of the mitotic kinesin CENP-E for treating certain cellular proliferation diseases

Growing community of inventors

West Chester, PA, United States of America

Dashyant Dhanak